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Marine snails of the genus Conus (‘cone snails’) are predatory
gastropod mollusks found on or near coral reefs in tropical waters
throughout the world. They have evolved an elaborate strategy
for the rapid immobilization of fish, worms or other mollusks
that involves the injection of a complex mixture of bioactive pep-
tides into their prey. These conopeptides are typically 
10–30 amino acid residues long and contain multiple intramol-
ecular disulfide bonds. The venom of any single Conus species
may contain more than 100 different peptides1. Conopeptides
interfere with neurotransmission by targeting a variety of pro-
teins expressed on the cell surface. Presently, distinct classes of
conopeptides are recognized to act at voltage-sensitive Ca2+ chan-
nels2, Na+ channels3–5, K+ channels6,7, nicotinic ACh recep-
tors8–10, 5-HT3 receptors
11, NMDA receptors12, vasopressin
receptors13 and neurotensin receptors14. The potential of
conopeptides as tools in neuroscience or as therapeutic agents
remains largely unexplored, given that the conopeptides charac-
terized to date are estimated to represent only 0.1% of the
conopeptides present in the ∼500 species of Conus15.
Here we describe the discovery and characterization of two
new classes of conopeptides: the ρ-conopeptide class defined by
conopeptide TIA from Conus tulipa, and the χ-conopeptide class
defined by conopeptides MrIA and MrIB from C. marmoreus
(Table 1, Fig. 1). Both classes interfere with the action of nora-
drenaline (NA), a key neurotransmitter in the central and
peripheral nervous systems. 1H NMR studies reveal marked dif-
ferences in the three-dimensional structures of these two-loop
peptides. To achieve their different pharmacologies, the 
ρ-conopeptides use a new combination of amino acids arranged
on an α-conopeptide fold (1–3, 2–4 disulfide connectivity),
whereas the χ-conopeptides use a different sequence and
conopeptide disulfide framework (1–4, 2–3).
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Cone snails use venom containing a cocktail of peptides (‘conopeptides’) to capture their prey.
Many of these peptides also target mammalian receptors, often with exquisite selectivity. Here
we report the discovery of two new classes of conopeptides. One class targets α1-adrenoceptors
(ρ-TIA from the fish-hunting Conus tulipa), and the second class targets the neuronal
noradrenaline transporter (χ-MrIA and χ-MrIB from the mollusk-hunting C. marmoreus). ρ-TIA
and χ-MrIA selectively modulate these important membrane-bound proteins. Both peptides act
as reversible non-competitive inhibitors and provide alternative avenues for the identification of
inhibitor drugs.
RESULTS
Peptide discovery
While searching for α-conopeptides (competitive antagonists of
the nicotinic ACh receptor), we isolated and sequenced the
polypeptides TIA ([M + 2H]2+, observed m/z = 1195.57, expect-
ed m/z = 1195.57; calculated and expected [M + H]+
m/z = 2390.15), MrIA ([M + H]+, observed m/z = 1408.53,
expected m/z = 1408.53), and MrIB ([M + H]+ observed 
m/z = 1393.52, expected m/z = 1393.55) from the crude venom of
C. tulipa and C. marmoreus collected from the Great Barrier Reef,
Australia (Table 1, Fig. 1). ([M + H]+ and [M + 2H]2+ refer to
the ionization states of the molecules, and m/z is the mass/charge
ratio determined by mass spectrometry.) Surprisingly, these
polypeptides had little sequence homology to previously identi-
fied conopeptides, despite the cysteine residues being positioned
in the linear sequence in a manner reminiscent of α-conopep-
tides. To allow investigations into their mechanisms of action and
three-dimensional structures, chemically identical synthesized
forms of these peptides were assembled.
Pharmacology
The likely modes of action of TIA and MrIA were identified from
studies of their effects on the biphasic contractile response of the
electrically stimulated rat prostatic vas deferens. Both peptides
affected the second phase of contraction, which peaks approxi-
mately 600 ms after stimulation due to the action of neurally
released NA on postjunctional α1-adrenoceptors
16. This NA-
mediated response was preceded by a faster contraction, which
peaked approximately 200 ms after stimulation due to the action
of the sympathetic co-transmitter ATP at postjunctional
P2X-purinoceptors17. TIA and MrIA had opposite effects on the
strength of the NA-mediated component of the vas deferens con-
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traction. TIA (concentration producing 50% inhibition (IC50),
500 nM) caused a concentration-dependent inhibition of the sec-
ond phase of the contraction, without affecting the ATP-medi-
ated response (Fig. 2a). This inhibition was slowly reversed upon
washout with conopeptide-free solution. In the epididymal seg-
ment of rat vas deferens, TIA (3 µM and 10 µM) increased the
concentration of exogenously applied NA required to produce
the half-maximal effect (EC50) by 5.5- and 17.8-fold, and
depressed the level of the maximum response to 82% and 42%
of the control response, respectively. Because the effects of TIA
were not surmountable, the peptide acted as a non-competitive
antagonist of NA-induced contractions in the vas deferens. The
concomitant decrease in NA potency is explained by the under-
lying hyperbolic relationship between α1-adrenoceptor activa-
tion and the contractile response in the rat vas deferens18. At
relatively low concentrations of a non-competitive α1-adreno-
ceptor antagonist, part of the receptor pool can be removed with-
out affecting the level of the maximum response. This gives rise
to the phenomenon of ‘spare receptors.’ The EC50 for NA is
increased in this situation because the fractional receptor occu-
pancy required to generate the half-maximal response is increased
with the reduction in the size of the available receptor pool. In
addition, the half-maximal response does not occur at 50% recep-
tor occupancy because of the underlying non-linear relationship
between receptor activation and response. As the receptor pool
is further diminished by increasing concentrations of a non-com-
petitive antagonist, the maximum response to NA is depressed.
This reduction in the level of the maximum response is accom-
panied by a rightward shift of the concentration–response curve
(that is, increased EC50). Again, this is due to the increase in the
fractional receptor occupancy required by NA to produce the
half-maximal response19.
To define the molecular pharmacology of TIA, we investigat-
ed its action on the cloned hamster
α1B-adrenoceptor expressed in COS-1
cells. TIA dose-dependently displaced
binding of the α1-adrenoceptor antago-
nist 125I-HEAT to α1B-adrenoceptors
(IC50, 124 nM) (Fig. 2b), confirming
that TIA is an inhibitor of the
α1-adrenoceptor. Thus, TIA belongs to
a previously unknown class of conopep-
tides we name ρ-conopeptides. This
inhibition was non-competitive, as sat-
uration binding studies revealed that
ρ-TIA (1 µM) reduced maximum
125I-HEAT binding to α1B-adrenocep-
tors by 85% without affecting the affin-
ity of the receptor for the radioligand
(Kd) (Fig. 2c). Thus, TIA acts non-com-
petitively to inhibit the binding
of agonists (NA) and antagonists
(HEAT) that act directly at the
NA binding site20.
In contrast to ρ-TIA, MrIA,
its amidated derivative
MrIA-NH2, and MrIB-NH2 caused
a concentration-dependent in-
crease in the second phase of the
contraction of the rat prostatic
vas deferens in response to elec-
trical field stimulation (Fig. 3a).
Again, the ATP-mediated re-
sponse was unaffected, and the effect of the peptides was reversed
upon washout. MrIA-NH2 (EC50, 430 nM), being 1.5- and 2-fold
more potent than MrIA and MrIB-NH2, respectively, was used to
establish the mechanism for this potentiation. Log concentra-
tion–response curves to exogenously applied NA were dose-depen-
dently shifted leftward in a parallel manner 3.3- and 7.4-fold by
MrIA-NH2 (1–3 µM), indicating that the sensitivity of the tissue
to NA was enhanced by the peptide. However, MrIA-NH2 (3 µM)
had no effect on the responsiveness of the tissue to methoxam-
ine. Because methoxamine is an α1-adrenoceptor agonist, but not
a substrate for the noradrenaline transporter21 (NET), we hypoth-
esized that MrIA-NH2 acts to inhibit the NET, the principal route
of elimination of NA from the synapse.
To define the molecular pharmacology of MrIA-NH2, we inves-
tigated its action on the cloned rat and human NET expressed
in COS-1 cells. The rate of cellular accumulation of 3H-NA via
the rat NET was reduced by MrIA-NH2 (IC50 615 nM) in a dose-
dependent manner (Fig. 3b). MrIA-NH2 also inhibited transport
of 3H-NA by the human NET (IC50, 1.26 µM). Thus, MrIA-NH2
is an inhibitor of the NET, making it the first of a previously
unknown class of conopeptides we name χ-conopeptides. This
action was found to be non-competitive in nature, as χ-MrIA-NH2
(1 µM) reduced the maximum rate of 3H-NA uptake by the
human NET by 42% without affecting the affinity of the trans-
porter for substrate (Km) (Fig. 3c). Of the family of monoamine
neurotransmitter transporters, χ-MrIA-NH2 is selective for the
NET, because at 100 µM it did not inhibit the closely related
human dopamine and serotonin transporters (data not shown).
A range of tissue assays were used to determine the selectivity
of the ρ- and χ-conopeptides. Responses of the guinea pig ileum
to nicotine and the mouse phrenic nerve–hemidiaphragm to elec-
trical stimulation were unaffected by ρ-TIA (10 µM) and
χ-MrIA-NH2 (3 µM), indicating that unlike the α-conopeptides,
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Fig. 1. Liquid chromatography/mass spectroscopy (LC/MS) analysis of crude venom from C. tulipa and
C. marmoreus. (a) TIA eluted as a minor component at 24.5 min (Inset C. tulipa shell). (b) MrIA eluted
at 21.8 min, and MrIB eluted as a minor component at 24.2 min (Inset  C. marmoreus shell). Over 90%
of the conopeptides present in the crude venom of these species have not been characterized.
a b
Table 1. Sequence and pharmacological diversity of 2-loop conopeptides.
Class Name Sequence Connectivity Physiological target
ρ TIA FNWRCCLIPACRRNHKKFC* 1–3, 2–4 α1-adrenoceptor
χ MrIA NGVCCGYKLCHOC 1–4, 2–3 noradrenaline transporter
MrIB VGVCCGYKLCHOC 1–4, 2–3
α GI ECCNPACGRHYSC* 1–3, 2–4 nicotinic acetylcholine
PnIB GCCSLPPCALSNPDYC* 1–3, 2–4 receptors
Cysteines involved in disulfide bonds are labeled 1–4 with respect to the linear sequences. *Amidated C-termini. O,
4-hydroxyproline. GI was isolated from Conus geographus8, and PnIB was isolated from C. pennaceus38.
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Fig. 2. Mode of action of ρ-TIA. (a) Inhibition of electrically evoked
contractions of the prostatic portion of the rat vas deferens by ρ-TIA.
(b) Displacement of 125I-HEAT binding to expressed α1B-adrenoceptor
by ρ-TIA. (c) Saturation curves for 125I-HEAT binding to the 
α1B-adrenoceptor expressed in COS-1 cells in the absence () and
presence of either 30 nM () or 1 µM () ρ-TIA. Symbols represent
the mean ± s.e.m. of n = 3 separate experiments performed in dupli-
cate. Some error bars are obscured by the symbols.
these peptides do not target neuronal or muscle subtypes of the
nicotinic ACh receptor. ρ-TIA and χ-MrIA-NH2 had no effect on
the first component of vas deferens contraction. Thus, both are
without effects on the voltage-sensitive ion channels involved in
action potential propagation and neurotransmitter exocytosis,
which are targeted by certain other conopeptide classes2,3,7. Local
anesthetic-type activity, such as blockade of neuronal Na+ chan-
nels, has been previously reported for prazosin and other
α1-adrenoceptor antagonists
22,23, and for cocaine24. Also unaffect-
ed by ρ-TIA (10 µM) were presynaptic α2-adrenoceptors, of which
the activation by NA inhibits evoked contractions in the prazosin-
treated rat vas deferens. χ-MrIA-NH2 did not affect contractions to
methoxamine, indicating that the peptide does not act at α1-adreno-
ceptors, distinguishing it from some other NET inhibitors, such as
the antidepressants desipramine and amitriptyline25.
Three-dimensional structures
To begin to understand the structural features underlying the
biological activity of ρ- and χ-conopeptides, we used 1H NMR
techniques to determine the structures of ρ-TIA and a repre-
sentative χ-conopeptide, χ-MrIB-NH2. ρ-TIA gave NMR spec-
tra with good NH chemical shift dispersion, indicative of a
well-structured molecule. A total of 213 distance restraints
derived from 17 intra-residue, 93 sequential, 67 medium and 36
long-range NOEs (nuclear Overhauser effects), 7 dihedral and
19 αH chemical shift restraints were obtained for ρ-TIA from
500 and 750 MHz data. In contrast, χ-MrIB-NH2 showed peak
‘brothering,’ indicating the presence of a minor conformation
(<10% relative population). However, changing the solvent con-
ditions to 30% acetonitrile/H2O or 30% TFE/H2O emphasized
the major conformation. Comparable NMR data were also
obtained for χ-MrIA and χ-MrIA-NH2, indicating similar struc-
tures among the χ-conopeptides. Like MrIB-NH2, these peptides
showed evidence for minor conformations, most likely associ-
ated with cis–trans isomerization of the His10–Hyp11 peptide
bond. This proposal is supported by a doubling of peaks for
residues flanking this bond (His11, Cys13) and those physically
close to it (Gly2, Val3) due to nearby disulfide linkages. The
major conformer clearly has a trans His10–Hyp11 peptide bond
based on a strong sequential His10αH→Hyp11δH NOE in all
of the χ-conopeptides, but the low intensity and limited number
of peaks observed for the minor conformers prevented their
definitive characterization. The possibility that configurational
isomerization of the disulfide bonds (ProR/ProS forms) also
contributes to the minor forms cannot be excluded. However,
whatever the cause of the minor forms, they are very similar in
overall structure to the major conformer, as the NH chemical
shifts of the brothered peaks are all within 0.05 p.p.m. of the
major conformer. A total of 82 distance restraints derived from
14 intra-residue, 42 sequential, 3 medium, 23 long range NOEs
and 4 dihedral restraints were obtained for the major confor-
mation of χ-MrIB-NH2 from 500 MHz data.
For both ρ-TIA and χ-MrIB-NH2, 50 structures were energy-
minimized, and the 20 lowest-energy structures were chosen to
represent the final structures (Fig. 4). ρ-TIA consisted of a stretch
of 310 helix between Arg4 to Leu8, a helical turn from Pro9 to
Arg12, followed by four nested β-turns between Arg12 and Cys19,
which almost comprised another turn of helix. These comprised
a type I β-turn between residues 12–15, and three type IV β-turns
between residues 13–16, 14–17 and 15–18. ρ-TIA had a back-
bone pairwise root-mean-square deviation (RMSD) of 0.73 Å
(1.94 Å for all heavy atoms), and no NOE violations greater than
0.2 Å (4 violations greater than 0.1 Å).
In contrast to ρ-TIA, χ-MrIB-NH2 contained no helical ele-
ments, and instead formed a small β-hairpin structure. Specifi-
cally, χ-MrIB-NH2 contained a flexible loop between Tyr7 and
Leu9, which was presented on the β-hairpin structure, with main-
chain H-bonds between Cys4 NH and His11 C=O (all structures),
and Gly6 NH and Leu9 C=O (13/20 structures). χ-MrIB-NH2 had
a backbone pairwise RMSD of 1.23 Å (2.90 Å for all heavy atoms)
and no NOE violations greater than 0.2 Å (3 violations greater
than 0.1 Å). Although the RMSD was higher than is typically seen
for larger proteins, it is not unusual for small peptides to exhibit
high RMSD values. NOEs are weaker than for larger proteins due
to correlation time effects, and small peptides lack a core region
that typically gives many NOE contacts. Both factors can lead to
lower precision (RMSD), but the structures reported here are suf-
ficient to define the global fold. In addition, χ-MrIB-NH2 was less
defined between residues Tyr7–Leu9, possibly reflecting flexibili-
ty in this region. With these residues excluded from the calcula-
tion, the backbone RMSD was 0.74 Å.
DISCUSSION
The ρ- and χ-conopeptides are the first examples of peptides that
act selectively at α1-adrenoceptors and the NET. Both classes act
allosterically through sites distinct from those targeted by nora-
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drenaline. They are structurally distinct from the various other
classes of small molecule inhibitors of the α1-adrenoceptor and
NET that act competitively at the site of NA interaction, many
of which are important therapeutic agents. Both ρ-TIA and
χ-MrIA-NH2 lack the common and often therapeutically limit-
ing pharmacology of α1-adrenoceptor antagonists (α2-adreno-
ceptor and Na+-channel inhibition) and NET inhibitors
(α1-adrenoceptor and muscarinic ACh receptor antagonism),
and thus may be useful clinically. Given the physical character-
istics of conopeptides, we expect that these peptides will not cross
the cell membrane, and that their site of action is on the extra-
cellular surface of these proteins. Previously, a peptide with
sequence identical to χ-MrIA was found to have antinociceptive
activity when administered intrathecally to mice26. This is not
unexpected given the role of NA in antinociception27, and indi-
cates that χ-MrIA may have potential as an analgesic.
ρ-TIA, with a 4/7 two-loop framework, adopts the canonical
α-conopeptide fold with a 1–3, 2–4 disulfide bond connectivity,
as exemplified by PnIB (Fig. 4). The ρ-TIA structure is also relat-
ed to the published X-ray structures for α-conopeptides 
[Tyr15]-PnIA, [Tyr15]-PnIB and [Tyr15]-EpI, with a backbone
RMSD of approximately 1.0 Å over the two loops28–30. Thus
ρ-conopeptides achieve their pharmacology by displaying dif-
ferent side-chain elements on a peptide backbone that can also
be used to target nicotinic ACh receptors. In contrast,
χ-MrIB-NH2 has a distinctly different structure. The presence of
a Cys5 αH to Cys13 NH NOE, strong Cys4 βH to Cys13 αH and
βH NOEs, and Cys5 αH to Cys10 αH NOE is not compatible
with the canonical 1–3, 2–4 disulfide bond connectivity, but is
instead indicative of a 1−4, 2−3 disulfide bond connectivity. This
connectivity was also shown chemically by selective reduc-
tion/alkylation studies (data not shown), and by the selective syn-
thesis of the three possible structural isomers26,31. Thus,
χ-conopeptides achieve their pharmacology through a conopep-
tide structure that uses different side-chain elements and a pre-
viously unidentified conopeptide backbone. Although we assume
that the observed activity for the χ-conopeptides arises from the
major (>90%) conformation described here, minor forms, most
likely associated with cis–trans isomerisation of Hyp11, do occur
in solution, and could potentially contribute to the biological
activity. In any case, these minor forms are very similar to the
major conformation and exhibit the same connectivity of disul-
fide bonds. Given that this is a previously unknown disulfide
arrangement for native conopeptides, it is not surprising that
χ-MrIB-NH2 superimposed poorly with α-conopeptides such as
GI (Fig. 4). For example, the heavy atom RMSD for the cysteine
residues of χ-MrIB-NH2 and GI was only 4.02 Å. These high-res-
olution three-dimensional structures of ρ- and χ-conopeptides
provide templates to guide the design of peptidomimetic
inhibitors of α1-adrenoceptors and the NET.
These two conopeptide classes open up alternative avenues
for modulating α1-adrenoceptors and the NET. Because these
peptides are non-competitive inhibitors, they seem to act alloster-
ically at modulatory sites distinct from the site of NA interaction,
presumably at the extracellular loops of these membrane-bound
proteins. These modulatory sites on the α1-adrenoceptor and the
NET may also be sites where endogenous mammalian peptide
inhibitors act. An example of such an endogenous modulatory
peptide is 5-HT-moduline, a non-competitive inhibitor of the
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Fig. 3. Mode of action of χ-MrIA-NH2. (a) Enhancement of electrically
evoked contractions of the prostatic portion of the rat vas deferens by
χ-MrIA-NH2. (b) Inhibition of 3H-NA uptake into COS-1 cells via
expressed rNET by χ-MrIA-NH2. (c) Kinetics of 3H-NA transport by
hNET expressed in COS-1 cells in the absence () and presence of 
1 µM χ-MrIA-NH2 (). Symbols represent the mean ± s.e.m. of n = 3
separate experiments performed in duplicate. Some error bars are
obscured by the symbols.
Fig. 4. NMR-derived structures of ρ-TIA and χ-MrIB-NH2. The NMR
structure of α-conopeptides PnIB and GI are shown for comparison.
Based on loop size, ρ-TIA (4/7) and χ-MrIB-NH2 (4/2) are closest in
structure to α-conopeptides PnIB (4/7) and GI (3/5), respectively.
Disulfide bonds are shown in red.
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5-HT1B/D G-protein-coupled receptor
32. It remains to be seen if
non-competitive modulatory sites are a common feature across
G-protein-coupled receptors and transporters.
The involvement of ρ-TIA and χ-MrIA in prey capture is less
clear, as neither conopeptide alone was toxic to Gambusia affinis
at 25 nmol/g. The peptides have not been tested for biological
activity in mollusks. It is possible that these peptides act (per-
haps even at a different physiological target in the prey species) in
a ‘cabal’ with other bioactive peptides in the venom to produce a
synergistic effect that aids prey capture33. The two-loop
CCXnCXnC peptides, in which X defines residues comprising the
intercysteine loops, seem to represent a ‘privileged’ structural
class that can access diverse pharmacology, reminiscent of the
four-loop CXnCCXnCXnCXnC peptides, which target voltage-
sensitive Ca2+ (ω-conopeptides)2, Na+ (µO-conopeptides)5 and
K+ (κ-conopeptides)7 ion channels. However, the two-loop struc-
tural class act at membrane proteins targeted by the neurotrans-
mitters NA (ρ- and χ-conopeptides) and ACh (α-conopeptides),
rather than at voltage-sensitive ion channels.
METHODS
Peptide isolation. The peptides were purified to homogeneity, and their
primary structures were determined by Edman sequencing, following
procedures previously described34. ρ-TIA, χ-MrIA and χ-MrIB were
identified in crude venom from C. tulipa and C. marmoreus
(0.6 mg/mL, 15 and 5 µL injected, respectively) by reverse-phase HPLC
using a C18 column (3.5 µm, 2.1 × 50 mm Zorbax 300 SB, Palo Alto, Cal-
ifornia) eluted with a 1% linear gradient from 0 to 60% B (A = 0.1%
formic acid, B = 90% acetonitrile/0.1% formic acid) using a HP1100
pump. The eluant was continuously monitored with a QSTAR pulsar
(PE-Sciex, Foster City, California) mass spectrometer. Mass spectrome-
try  and sequence data indicated that the C-terminus of ρ-TIA is ami-
dated, whereas χ-MrIA and χ-MrIB are the free-acid forms.
Peptide synthesis. ρ-TIA (amidated), χ-MrIA (amidated and free-acid)
and χ-MrIB (amidated) were synthesized using Fmoc and Bmoc chem-
istry, and oxidized in NaHCO3, pH 8.0
34. The final overall yield was 65%
for TIA and 30% for MrIA, with purity greater than 98% by HPLC. On
coinjection onto a Waters C18 symmetry column (Milford, Massachus-
sets), TIA (amidated) coeluted with native TIA, and HPLC purified MrIA
(free acid), but not the amidated form of MrIA, coeluted with native MrIA.
Rat vas deferens. Segments of vasa deferentia from male Wistar rats
(250–350 g) were mounted under a tension of 0.5 g in 5 mL organ baths
containing 119 mM NaCl, 4.7 mM KCl, 1.17 mM MgSO4, 1.18 mM
KH2PO4, 25.0 mM NaHCO3, 5.5 mM glucose, 2.5 mM CaCl2 and 
0.026 mM EDTA (pH 7.4, 37°C, bubbled with 5% CO2:95% O2). Bisect-
ed prostatic segments were field-stimulated with single electrical pulses
of 55-V amplitude and 1-ms duration generated by a Grass S44 stimu-
lator (Quincy, Massachussets) at 3-min intervals. Isometric contractions
were recorded digitally on a Power Macintosh computer with a
MacLab/8s data acquisition system (ADInstruments, Sydney, Australia).
The resulting contractions could be abolished by tetrodotoxin (0.1 µM),
indicating a neural origin. Drugs were added cumulatively to the organ.
All animal experiments were conducted with the approval of the Uni-
versity of Queensland Animal Experimentation Ethics Committee.
To examine if ρ-TIA affected presynaptic α2-adrenoceptors, electri-
cal pulses as described above were delivered at 20-s intervals to the pro-
static portion of vas deferens treated with prazosin (0.5 µM). Cumulative
concentration–response curves for the inhibitory effect of NA were estab-
lished before and 20 min after addition of ρ-TIA (10 µM). To determine
whether ρ-TIA affected postjunctional contractile responses to NA, we
used unstimulated bisected epididymal segments. Cumulative concen-
tration–response curves to NA were established in the absence or presence
of ρ-TIA (3 µM or 10 µM applied 20 min before NA). The bisected epi-
didymal segments were also used to establish concentration–response
curves to NA and methoxamine in the absence and presence of
χ-MrIA-NH2. χ-MrIA-NH2 (1 µM or 3 µM) was applied 20 min before
cumulative additions of NA or methoxamine, which contract the smooth
muscle via postjunctional α1-adrenoceptors.
Mouse phrenic nerve–hemidiaphragm. Left and right hemidiaphragm
were dissected from male Quackenbush mice (20–30 g), mounted under
a tension of 1.0 g in 5 mL organ baths containing 135.0 mM NaCl, 
5.0 mM KCl, 2.0 mM CaCl2, 1.0 mM MgCl2, 11.0 mM glucose, 15.0 mM
NaHCO3 and 1.0 mM KH2PO4 (pH 7.4, 37°C, bubbled with 5%
CO2:95% O2). Field stimulation of the phrenic nerve with 3-V pulses of
0.2-ms duration delivered at 20-s intervals evoked contractions recorded
as described above. We examined the effect of ρ-TIA (10 µM) and
χ-MrIA-NH2 (3 µM) on the contractions.
Guinea pig ileum. Segments of ilea (∼1.5 cm) from male guinea pigs
(280–430 g) were mounted under a resting tension of 1.0 g in 5 mL organ
baths containing 136.9 mM NaCl, 2.68 mM KCl, 1.84 mM CaCl2, 1.03
mM MgCl2, 5.55 mM glucose, 11.9 mM NaHCO3, 0.45 mM KH2PO4 and
10 µm indomethacin (pH 7.4, 37°C, bubbled with 5% CO2:95% O2). Non-
cumulative doses of nicotine (4 µM) were added until reproducible con-
tractile responses were obtained. Tissue was then exposed to the ρ-TIA (10
µM) or χ-MrIA-NH2 (3 µM) for 25 min and nicotine was again applied.
125I-HEAT binding. Membranes from COS-1 cells (ATCC, Manassas, Vir-
ginia) grown in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 5% fetal bovine serum and transiently transfected with plasmid DNA
encoding the hamster α1B-adrenoceptor were prepared as described pre-
viously20. For radioligand binding studies, we used duplicate tubes con-
taining 80 pM 125I-HEAT, COS-1 membranes and various concentrations
of ρ-TIA, in HEM buffer (20 mM HEPES, 1.5 mM EGTA, 12.5 mM
MgCl2, pH 7.5). For saturation binding studies, 
125I-HEAT was added to
575 nM in the presence and absence of TIA. Total reaction volume was
250 µL. Nonspecific binding (5–10% of total) was determined by the
inclusion of phentolamine (10–4 M). After 80 min of incubation at room
temperature, the reactions were stopped by the addition of ice-cold HEM
buffer and were transferred onto Whatman GF/C glass filters (Kent, UK).
Uptake of 3H-NA. COS-1 cells grown in 24-well plates containing DMEM
and 10% fetal bovine serum were transiently transfected with plasmid
DNA encoding the rat35 or human NET36 using Lipofectamine 2000
reagent (Gibco, Carlsbad, California). Assays were done at room tem-
perature, 24 h after transfection in transport buffer containing 125 mM
NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.3 mM CaCl2,
25 mM HEPES, 5.55 mM D-(+)-glucose, 1.02 mM ascorbic acid, 10 µM
U-0521 and 100 µM pargyline, pH 7.4. The cells were exposed to vari-
ous concentrations of χ-MrIA-NH2 or desipramine (10−5 M; for the deter-
mination of nonspecific accumulation) for 15 min before 3H-NA 
(100 nM, supplemented with unlabeled NA as required) was added for
either 8 (rat NET) or 20 min (human NET). 3H-NA was added at con-
centrations up to 30 µM to determine the kinetics of NA transport by
hNET expressed in COS-1 cells. The solution was then rapidly removed,
and the cells were washed with ice-cold PBS. The cells were lysed with
0.1% Triton-X-100 in 10 mM Tris·HCl (pH 7.5) for 90 min, and the cell
lysate was taken for scintillation counting.
Drugs. The following drugs were used: desipramine hydrochloride,
indomethacin, methoxamine hydrochloride, nicotine hydrogen tartrate
(–)-noradrenaline bitartrate (NA), pargyline, tetrodotoxin (Sigma, St. Louis,
Missouri); phentolamine mesylate (Research Biochemicals International,
Natick, Massachussets); U-0521 (Biomol, Plymouth Meeting, Pennsylva-
nia); 125I-HEAT, 3H-NA (NEN Life Science, Boston, Massachussets).
Statistics and data analysis. Data are expressed as means ± s.e.m. of
results obtained from 3–6 separate experiments. Student’s two-tailed t-test
or analysis of variance was used for statistical evaluation; values of p less
than 0.05 were considered significant. Sigmoidal concentration–response
curves for the calculation of EC50 or IC50 values were fit by non-linear
regression using Prism software (GraphPad, San Diego, California).
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NMR studies. NMR experiments were typically done on 2−5 mM peptide
in either D2O or 90% H2O/10%D2O at pH 3.5 and 278−285 K. Addi-
tional data on χ-MrIA-NH2 were obtained in 30% d3-acetonitrile/10%
D2O/60% H2O and 30% TFE/10% D2O/60% H2O. Spectra were acquired
on ARX 500 MHz or AVANCE 750 MHz spectrometer (Bruker, Billerica,
Massachussets) equipped with a shielded gradient unit, and referenced
to a DSS internal standard. Spectra were processed using UXNMR or
XWIN-NMR (Bruker), and analyzed in Felix (Hare Research, Bothell,
Massachussets). NOE crosspeaks were assigned as strong (1.8−2.7 Å),
medium (1.8−3.5 Å) or weak (1.8−5.0 Å). NOE peaks observed at long
mixing times (≥400 ms) but not at shorter mixing times were classed as
very weak (1.8−6 Å). Pseudo-atom corrections of 1.5 Å for methyl, 1.0
Å for methylene, and 2.0 Å for phenyl and tyrosine ring protons were
added. Structures were calculated from distance and angle restraints using
the torsion-angle dynamics/simulated annealing protocol as previously
described37. After the initial structures showed discrepancies due to the
unusual disulfide connectivity in χ-MrIB-NH2, the simulated annealing
protocol was modified to first calculate the structures without disulfide
bonds. With this protocol, 41/50 structures had the preferred disulfide
connections 4−13 and 5−10. Incorporating this disulfide connectivity
into the simulated annealing protocol improved structural convergence.
The coordinates for ρ-TIA and χ-MrIB-NH2 have been deposited with
the Research Collabatory for Structural Biology (RCSB) with accession
codes RCSB013213 (PDB ID 1IEN) and RCSB013214 (PDB 1IEO).
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